6-isopropyl-3-methyl-3H-benzooxazol-2-one | 31554-68-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 英文名称: 6-isopropyl-3-methyl-3H-benzooxazol-2-one
• 英文别名: 3-Methyl-6-propan-2-yl-1,3-benzoxazol-2-one
• CAS: 31554-68-4
• 化学式: C₁₁H₁₃NO₂
• 分子量: 191.23
• InChiKey: BTXWBKUMMDRROA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-苯并唑啉酮 在 sodium hydroxide 、 硫酸 作用下， 生成 6-isopropyl-3-methyl-3H-benzooxazol-2-one
  参考文献：
  名称：

  Lespagnol,C. et al., Bulletin de la Societe Chimique de France, 1971, p. 552 - 556

  摘要：

  DOI：

文献信息

• CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS
  申请人：Singh Rajinder

  公开号：US20100130486A1

  公开（公告）日：2010-05-27

  The invention encompasses compounds having formula I or II and the compositions and methods using these compounds in the treatment of conditions in which inhibition of PKC and PKD is therapeutically useful.

  本发明涵盖具有公式I或II的化合物，以及使用这些化合物治疗抑制PKC和PKD在治疗上有用的情况的组合物和方法。
• SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND, THEIR PREPARATION AND USE IN MEDICAMENTS
  申请人：Mas Prio Josep

  公开号：US20090209528A1

  公开（公告）日：2009-08-20

  The present invention relates to substituted tetrahydroisoquinoline compounds of general formula (I), a process for their preparation, medicaments comprising said substituted tetrahydroisoquinoline compounds as well as the use of said substituted tetrahydroisoquinoline compounds for the preparation of medicaments, which are particularly suitable for the prophylaxis and/or treatment of disorders or diseases that are at least partially mediated via 5-HT 6 receptors.

  本发明涉及一般式(I)的取代四氢异喹啉化合物，其制备方法，包含所述取代四氢异喹啉化合物的药物以及利用所述取代四氢异喹啉化合物制备药物，特别适用于预防和/或治疗至少部分通过5-HT6受体介导的疾病或疾病的用途。
• SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS
  申请人：LABORATORIOS DEL DR. ESTEVE, S.A.

  公开号：EP2007729B1

  公开（公告）日：2012-06-27
• SULFONYLUREA DERIVATIVE CAPABLE OF SELECTIVELY INHIBITING MMP-13
  申请人：Endoh Takeshi

  公开号：US20100099676A1

  公开（公告）日：2010-04-22

  A compound represented by the general formula (I): wherein R 1 is wherein R 26 and R 28 are each independently lower alkyloxy and the like; n 1 is an integer of 0 to 3; Z is a optionally substituted C1-C5 alkynylene which may be interrupted with a substituent selected from Substituent group a and the like; A is a group represented by the formula: wherein R 6 and R 7 are each independently lower alkyl and the like; m and n are each independently 0, 1, or 2; R 2 is a hydrogen atom and the like; R 3 is optionally substituted lower alkyl and the like; R 4 is a hydrogen atom; or R 3 and R 4 may be taken together with an adjacent carbon atom to from a ring; R 5 is hydroxyl and the like, or an optically active isomer, a pharmaceutically acceptable salt or a solvate thereof.
• FUSED PYRIMIDINE PYRIDINONE COMPOUNDS AS JAK INHIBITORS
  申请人：THERAVANCE BIOPHARMA R&D IP, LLC

  公开号：US20210188844A1

  公开（公告）日：2021-06-24

  The disclosure provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The disclosure also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat gastrointestinal inflammatory diseases.